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selected Asu-ACR-16 from a significant nematode parasite genus, Ascaris suum, as a pharmaceutical 
target and nicotine as our basic moiety (EC50 6.21 ± 0.56 μM, Imax 82.39 ± 2.52%) to facilitate the 
development of more effective anthelmintics. 
We expressed Asu-ACR-16 in Xenopus oocytes and used two-electrode voltage clamp electrophysiology 
to determine agonist concentration-current-response relationships and determine the potencies (EC50s) 
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Here, we describe the synthesis of a novel agonist, (S)-5-ethynyl-anabasine, and show that it is more 
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a b s t r a c t
Nematode parasites infect ~2 billion people world-wide. Infections are treated and prevented by
anthelmintic drugs, some of which act on nicotinic acetylcholine receptors (nAChRs). There is an unmet
need for novel therapeutic agents because of concerns about the development of resistance. We have
selected Asu-ACR-16 from a significant nematode parasite genus, Ascaris suum, as a pharmaceutical target
and nicotine as our basic moiety (EC50 6.21 ± 0.56 mM, Imax 82.39 ± 2.52%) to facilitate the development of
more effective anthelmintics.
We expressed Asu-ACR-16 in Xenopus oocytes and used two-electrode voltage clamp electrophysiology
to determine agonist concentration-current-response relationships and determine the potencies (EC50s)
of the agonists.
Here, we describe the synthesis of a novel agonist, (S)-5-ethynyl-anabasine, and show that it is more
potent (EC50 0.14 ± 0.01 mM) than other nicotine alkaloids on Asu-ACR-16. Agonists acting on ACR-16
receptors have the potential to circumvent drug resistance to anthelmintics, like levamisole, that do
not act on the ACR-16 receptors.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Our research has had a focus on nicotinic acetylcholine re-
ceptors (nAChRs) of parasitic nematodes because they are target
sites that bind a major class of anthelmintic drugs. nAChRs are
pentameric ligand-gated ion channels involved in synaptic trans-
mission in the nervous systems of both vertebrates and in-
vertebrates (Taly et al., 2009); these receptor channels also serve
other functions including paracrine functions in non-excitable tis-
sues (Proskocil et al., 2004). The nAChRs are activated by the ligand
agonists: acetylcholine (ACh), nicotine and structurally related
derivatives, that produce opening of their transmembrane ion-
channel and flux of sodium, potassium and sometimes calcium
ions across the membrane.
The agonist-binding sites of nAChRs have been well studied by
photolabeling, mutagenesis and electrophysiology (Arias, 2000).
Our understanding of ligand-receptor interactions has improved
following co-crystal structure studies of invertebrate acetylcholine
binding proteins (AChBPs) with cholinergic ligands (Sixma and
Smit, 2003; Rucktooa et al., 2009). AChBPs are homologs of the
extracellular agonist-binding site domain of nAChRs that share
20e24% nucleotide sequence identity with the extracellular
domain of AChRs (Blum et al., 2010). The agonist-binding site of
nAChRs is in the extracellular domain at the interface between the
principal subunit (that is an alpha subunit with vicinal cysteines)
and the adjacent complementary subunit. Five aromatic amino
acids in the agonist-binding site are highly conserved in nAChRs,
some of which contribute to the cation-p interactions with the
cationic nitrogen in agonists (Dougherty, 2013). Another feature of
nAChR agonists is the hydrogen bond acceptor, which is about
4e6 Å from the cationic nitrogen. Based on the high-resolution
structures of AChBPs, the hydrogen bond acceptor of the agonist
is stabilized by a water molecule, which interacts with the carbonyl
or the amide backbones of two less conserved residues (L102 and
M114) on loop E of the complementary subunit through three
hydrogen bonding interactions (Van Arnam and Dougherty, 2014).
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Ascaris, a genus of clade III nematode parasites, are gastroin-
testinal roundworms that infect humans, pigs and other animals
worldwide (Taylor et al., 2016) and have been estimated to cause
more than 1.2 billion human infections (de Silva et al., 2003). In
developing countries, the control of Ascaris infection relies on the
limited number of available anthelmintic drugs. Drug resistance in
various nematodes has been reported following frequent use of
anthelmintics (Garcia et al., 2016). There is an unmet need for novel
effective drugs which would overcome development of resistance
to existing anthelmintics.
The ACR-16 nicotinic acetylcholine receptor of Ascaris suum
(Asu-ACR-16) is a nematode homopentameric receptor, which re-
sembles vertebrate a7 nAChRs (Mongan et al., 2002). Asu-ACR-16 is
widely distributed in A. suum tissues but its physiological function
remains to be determined (Abongwa et al., 2016; Zheng et al., 2016).
As one of the recently characterized nematode parasitic nAChRs,
Asu-ACR-16 is pharmacologically different to its host a7 nAChR and
may be exploited as an anthelmintic drug target to counter resis-
tance to cholinergic anthelmintics directed at other pharmacolog-
ical types of nAChR (Holden-Dye et al., 2013; Zheng et al., 2016).
The agonist-binding site of Asu-ACR-16 receptors can be pre-
dicted by homology modeling using the human a7 nAChR chimera
as structural template, which shares 38% identity and 73% similarity
in amino acid sequence. Five conserved aromatic residues and two
hydrogen-bond interacting residues have orientations very close to
corresponding residues in other nAChRs, facilitating our investi-
gation of drug-receptor interactions of the Asu-ACR-16 receptor
(Zheng et al., 2016).
We know that the Asu-ACR-16 receptor is sensitive to six nico-
tinic agonists: nicotine, ACh, cytisine, 3-bromocytisine, epibatidine,
dimethyl-4-phenyllpiperazinium iodide (DMPP), but insensitive to
other cholinergic anthelmintic agonists (Abongwa et al., 2016). All
six of the Asu-ACR-16 agonists share the nicotinic pharmacophore:
a cationic nitrogen separated by ~5 Å from a hydrogen bond
acceptor. Here we use a combination of structural modeling and
synthetic strategy based on the nicotinic pharmacophore to explore
the pharmacological profiles of nicotine derivatives on the Asu-
ACR-16 receptor.
2. Materials and methods
2.1. Homology modeling and docking
The Asu-ACR-16 sequence is available in UniProtKB under the
accession number F1KYJ9 (Wang et al., 2011). Three crystal struc-
tures of a human a7 nAChR chimera co-crystalized with ligands of
different modes of action were used as templates (Table 1) to build
three different bound-formmodels of the ECD-Asu-ACR-16 (Li et al.,
2011; Huang et al., 2013; Zheng et al., 2016). Smiles strings of
nicotine derivatives were obtained from the ZINC website (http://
zinc.docking.org/search/structure) and converted to PDBQT
format for our docking studies. Docking of these ligands was per-
formed at the orthosteric ligand-binding sites of agonist-bound,
apo (no ligand) and antagonist-bound forms of the ECD-Asu-ACR-
16 models using AutoDock Vina Software (Trott and Olson, 2010;
Zheng et al., 2016). We investigated the intermolecular in-
teractions in ourmodels by comparing the intermolecular distances
in the crystal structures and our models ( 1 Å difference).
2.2. Expression and electrophysiology of Asu-ACR-16 in oocytes
Full length cRNA of Asu-acr-16 and the ancillary gene, Asu-ric-3
(UniProtKB accession number: F1L1D9_ASCSU). were prepared
using the previously described methods (Zheng et al., 2016). A
cRNA mixture of 25 ng Asu-acr-16 and 5 ng Asu-ric-3 cRNA in 50 nL
RNAse-free water was injected into de-folliculated Xenopus laevis
oocytes (Ecocyte Bioscience, Austin, TX, USA). The injected oocytes
were incubated in incubation solution (100 mM NaCl, 2 mM KCl,
1.8 mM CaCl2$2H2O, 1 mM MgCl2$6H2O, 5 mM HEPES, 2.5 mM Na
pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, pH 7.5) at
19 C for 4e8 days, with 100 mM BAPTA-AM added ~3 h before
recording.
A two-electrode voltage-clamp technique was used to record
currents from the Asu-ACR-16 receptor expressed in the Xenopus
oocytes. The oocyteswere kept in recording solution (100mMNaCl,
2.5 mM KCl, 1 mM CaCl2$2H2O and 5 mM HEPES, pH 7.3) and
clamped to 60 mV. Inward currents were induced by addition of
chemicals that acted as agonists that opened the nicotinic ion-
channel receptors. An Axoclamp 2B amplifier (Molecular Devices,
CA, and USA) was used to record the currents that were acquired
with Clampex 9.2 (Molecular Devices, CA, USA) software and
analyzed using GraphPad Prism 5.0 (GraphPad Software Inc. CA,
USA).
2.3. Chemicals used for synthesis
The following chemicals were used for the synthesis of (S)-5-
bromonicotine, (S)-5-bromoanabsine and (S)-5-ethynyl-anabsine:
4,4’-di-tert-butyl-2,2’-dipyridyl (dtbpy), copper (II) bromide
(CuBr2), 2-methyl-3-butyn-2-ol, triethylamine (Et3N) and N,N-dii-
sopropylethylamine (DIPEA) obtained from Sigma-Aldrich (St
Louis, MO, USA); di-m-methoxobis (1,5-cyclooctadiene)diiridium(I)
([Ir(COD) (OMe)]2) and methanesulfonato (2-di-t-butylphosphino-
20,40,6'-tri-i-propyl-1,1'-biphenyl) (2'-amino-1,1'-biphenyl-2-yl)
palladium (II) (Pd(PPh3)2Cl2) obtained from Strem Chemicals
(Newburyport, MA, USA); (S)-nicotine, (S)-anabasine and copper(I)
iodide (CuI) obtained from Alfa Aesar (Ward Hill, MA, USA); bis(-
pinacolato)diboron (B2pin2) obtained from Matrix Scientific
(Columbia, SC, USA); (trimethylsilyl)acetylene and di-tert-butyl
dicarbonate (Boc2O) obtained from Oakwood Products (Estill, SC,
USA); dichloromethane (DCM), trifluoroacetic acid (TFA), methanol
(MeOH), tetrahydrofuran (THF) and potassium carbonate (K2CO3)
obtained from Fisher Scientific (Waltham, MA, USA).
2.4. General synthetic experiment
All air-sensitive procedures were conducted under an inert at-
mosphere of a nitrogen-filled dry box or by standard Schlenk
techniques. All reactions were performed under an atmosphere of
nitrogen unless otherwise stated. All glassware for moisture
Table 1
Structural information for the ECD-Asu-ACR-16 and two of its homologous proteins (human a7 nAChR chimera and Lst-AChBP).
protein Organism PDB code Resolution (A) Ligand Pharmacology
ECD-ACR-16 Ascaris suum
a7 nAChR Homo sapiens & 3SQ6 2.8 epibatidine agonist
chimera Lymnaea stagnalis 3SQ9 3.1 none none
4HQP 3.51 a-bungarotoxin antagonist
AChBP Lymnaea stagnalis 1UW6 2.2 nicotine agonist
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sensitive reactions was dried at 140 C in an oven. THF and DCM
were degassed by purging with argon for 45 min and dried with a
solvent purification system by passing through a one-meter col-
umn of activated alumina. Flash column chromatography was
performed on Fisher brand silica gel 60 (230e400 mesh). Products
were visualized on TLC by UV light or by staining with KMnO4,
phosphomolybdic acid or ceric ammonium molybdate. HRMS (ESI)
analysis was performed at the Iowa State University Chemical
Instrumentation Facility on an Agilent 6540 QTOF spectrometer.
NMR spectra were acquired on Varian MR-400 and Bruker Avance
III 600 spectrometers at the Iowa State University Chemical
Instrumentation Facility. Chemical shifts are reported in ppm
relative to a residual solvent peak (CDCl3 ¼ 7.26 ppm for 1H and
77.0 ppm for 13C). Coupling constants are reported in hertz.
2.5. Synthesis of (S)-5-bromonicotine
Synthesis of (S)-5-bromonicotine was carried out following the
published procedure (Liskey et al., 2010):
2.6. Synthesis of (S)-tert-butyl-2-(pyridine-3-yl)piperidine-1-
carboxylate
Synthesis of compound -1, (S)-tert-butyl 2-(pyridin-3-yl)piper-
idine-1-carboxylate, below, was conducted using the following
approach.
Boc2O (3.30 g, 15.1 mmol, 1.10 equiv) was added to a solution of
(S)-anabasine (2.23 g, 13.7 mmol, 1.0 equiv) and Et3N (2.10 mL,
15.1 mmol, 1.10 equiv) in THF at 0

C. The reaction mixture was
stirred for 10 min and warmed to room temperature. After stirring
for 2 h, the mixture was diluted with water, and extracted with
EtOAc (3). The organic layers were combined, dried over Na2SO4
and concentrated under reduced pressure. The crude product was
purified by flash column chromatography on silica gel (1:1 hex-
ane:EtOAc) to yield compound 1, (S)-tert-butyl 2-(pyridin-3-yl)
piperidine-1-carboxylate in 95% yield (3.40 g, 13.1 mmol) as a pale
yellow liquid (confirmed by 1H NMR (CDCl3, 400 MHz) d 1.36e1.69
(m, 4H), 1.46 (s, 9H), 1.91e2.00 (s, 1H), 2.27 (d, J ¼ 14.0 Hz, 1H),
2.69e2.76 (m,1H), 4.07 (d, J¼ 14.8 Hz,1H), 5.47 (br, s,1H), 7.34e7.38
(m, 1H), 7.63 (d, J ¼ 7.6 Hz, 1H), 8.50 (s, 1H), 8.52 (s, 1H): spectral
data matched the literature precedent, (Beng and Gawley, 2011).
2.7. Synthesis of (S)-tert-butyl 2-(5-bromopyridin-3-yl)piperidine-
1-carboxylate
Synthesis of compound -2, (S)-tert-butyl 2-(5-bromopyridin-3-
yl)piperidine-1-carboxylate from compound 1 was carried out
as described below.
In a nitrogen-filled glove box, compound -1 (1.31 g, 5.0 mmol),
B2pin2 (1.12 mg, 4.4 mmol), [Ir(COD) (OMe)]2 (99.5 mg, 0.150mmol,
0.030 equiv), dtbpy (80.5 mg, 0.030 mmol, 0.060 equiv), and THF
(8.0 mL) were combined in a vial. The reaction mixture was then
sealed and heated at 80 C for 16 h. After the reaction mixture was
cooled to room temperature, the volatiles were removed under
vacuum. The residue was dissolved in 50.0 mL of MeOH and
50.0 mL of distilled water followed by CuBr2 (3.35 g, 15.0 mmol).
The flask was then sealed and heated at 80 C for 16 h. The reaction
mixture was cooled to room temperature, and 30% NH4OH (aq)
(20.0 mL) was added to the reaction mixture. The reaction mixture
was extracted with EtOAc (3 ), and the organic layers were
combined, washed with brine, and dried over Na2SO4. The product
was purified by column chromatography using silica gel (3:1 hex-
ane:EtOAc) to give compound -2, (S)-tert-butyl 2-(5-bromopyridin-
3-yl)piperidine-1-carboxylate in 36% yield (618 mg,1.80 mmol) as a
pale yellow solid. 1H NMR (400 MHz, CDCl3) d 1.30e1.69 (m, 4H),
1.46 (s, 9H), 1.89e1.98 (s, 1H), 2.24 (dd, J ¼ 16.0, 2.0 Hz, 1H),
2.68e2.75 (m,1H), 4.07 (d, J¼ 15.6 Hz, 1H), 5.43 (s, 1H), 7.69 (s, 1H),
8.42 (s, 1H), 8.56 (s, 1H); 13C NMR (100.5 MHz, CDCl3) d 19.2, 25.0,
27.7, 28.3, 40.2, 51.2, 80.2, 120.9, 137.1, 138.1, 146.4, 148.8, 155.2;
HRMS (ESI) calcd. For C15H22BrN2O2þ [MþH]þ 341.0859, found
341.0864, Fig. S1.
2.8. Synthesis of (S)-5-bromoanabasine
Synthesis of (S)-5-bromoanabasine, was prepared from com-
pound -2 as described below.
To a solution of compound 2 (93.0 mg, 0.273 mmol, 1.0 equiv) in
DCM (5.0 mL), TFA (1.0 mL) was added dropwise. The reaction
mixture was stirred at room temperature for 12 h. The mixture was
diluted with saturated NaHCO3 and extracted with EA (3). The
organic layers were combined, dried over Na2SO4 and concentrated
under reduced pressure. The crude product was purified by flash
column chromatography on silica gel (10:1 hexane:EtOAc to 10:1
EtOAc:Et3N) to give (S)-5-bromoanabasine in 83% yield (54.4 g,
0.226 mmol) as a pale yellow solid. 1H NMR (400 MHz, CDCl3)
d 1.43e1.55 (m, 3H), 1.65e1.68 (m, 1H), 1.75e1.78 (m, 1H), 1.89 (brs,
2 H), 2.74e2.80 (m, 1H), 3.18 (d, J ¼ 11.6 Hz, 1H), 3.61e3.63 (m, 1H),
7.89 (t, J ¼ 1.6 Hz, 1H), 4.7 (d, J ¼ 1.6 Hz, 1H), 8.53 (d, J ¼ 2.0 Hz, 1H);
13C NMR (151.0 MHz, CDCl3) d 25.0, 25.5, 34.8, 47.4, 59.1, 120.8,
136.9,142.5,146.7,149.6; HRMS (ESI) calcd. For C10H14BrN2þ [MþH]þ
241.0335, found 241.0332, Fig. S2.
2.9. Synthesis of (S)-5-ethynyl-anabasine
Synthesis of (S)-5-ethynyl-anabasine, was prepared from (S)-5-
bromoanabasine as described below.
In a nitrogen-filled Schlenk tube, compound 2 (247 mg,
1.02 mmol) in THF (3.0 mL), Pd(PPh3)2Cl2 (143 mg, 0.204 mmol,
0.20 equiv), CuI (39.0 mg, 0.204 mmol, 0.20 equiv), DIPEA (3.0 mL),
and trimethylsilylacetylene (0.16 mL, 1.12 mmol, 1.10 equiv) were
added. The mixture was stirred at 70 C for 16 h. After cooled to
room temperature, the mixture was filtered through a short pad of
silica gel and washed with ethyl acetate The filtrate was concen-
trated and purified by short silica gel column (100:1 hexane:EtOAc
to hexane:EtOAc 5:1) to give the crude product, which was used
directly for next step.
To a solution of the crude product in DCM (10.0 mL), TFA
(10.0 mL) was added. The mixture was stirred at rt for 2 h. All the
volatiles were removed under reduced pressure. The crude product
was purified by short silica gel column (2:1 hexane:EtOAc to 8:1
EtOAc:Et3N).
To a solution of the above crude product in MeOH (10.0 mL),
K2CO3 (568 mg, 4.08 mmol) was added. The mixture was stirred at
room temperature for 16 h. After filtration and concentration, the
product was purified by column chromatography using silica gel
(5:1 hexane:EtOAc to 10:1 EtOAc:Et3N) to give (S)-5-ethynyl-ana-
basine in 7% yield (12.8 mg, 0.0714 mmol) as a pale yellow liquid.
1H NMR (400 MHz, CDCl3) d 1.45e1.57 (m, 3H), 1.66e1.69 (m, 1H),
1.77e1.79 (m, 1H), 1.90 (brs, 1H), 2.07 (brs, 1H), 2.76e2.81 (m, 1H),
3.18 (s, 1H), 3.19 (d, J ¼ 12.0 Hz, 1H), 3.62e3.65 (m, 1H), 7.84 (t,
J ¼ 2.0 Hz, 1H), 8.54 (s, 1H), 8.59 (s, 1H); HRMS (ESI) calculated. For
C12H15N2þ [MþH]þ187.1230, found 187.1232, Fig. S3.
2.10. Pharmacological characterization of nicotinic derivatives and
data analysis
The aqueous soluble compounds: acetylcholine (ACh), (S)-
nicotine, (S)eSIB 1508Y, (S)-1-methylnicotinium, (S)-1’-methyl-
nicotinium, nornicotine, (S)-cotinine, (S)-anabasine, (S, R)-
anabasine were dissolved in recording solution at the
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concentrations described in the results. Non-polar compounds
were dissolved initially in DMSO tomake 100mM stock solutions of
each. Subsequently theywere diluted in recording solution to give a
concentration of DMSO of <0.1%.
100 mMACh was applied first to each oocyte for 10 s to check for
robust Asu-ACR-16 expression. In all oocyte recordings the peak
current response to 100 mMACh was used to normalize subsequent
current responses in that oocyte. Recording solution was then used
to wash out the drug from the oocytes for 3 min prior to next
application of drug perfusion.
Nicotine derivatives that elicited inward currents at 100 mM
were classed as agonists. To further characterize the nicotine de-
rivative agonists, increasing concentrations of the derivatives were
applied for 10 s (3 min wash intervals between drug applications).
The resulting dose-response relationships were described by the
Hill equation to give estimates of the EC50 (mM), Hill slope (nH),
maximum response (Imax, %) and expressed as mean ± S.E.M.
(N¼ 5) using GraphPad Prism 5.0 (Graphpad Software Inc. CA, USA).
2.11. Drugs
ACh, ()-nicotine hydrogen tartrate salt ((S)-nicotine), anaba-
sine ((S, R)-anabasine), (±)-nornicotine (nornicotine), 5-(1-methyl-
pyrrolidin-2-yl)-pyridin-2-ylamine dihydrochloride (6-AN) and
()-cotinine ((S)-cotinine) were purchased from Sigma-Aldrich (St
Louis, MO, USA). SIB 1508Y maleate ((S)eSIB 1508Y) was obtained
from Tocris Bioscience (Ellisville, MO, USA). (S)-anabasine, rac-5-
methylnicotine (5-methylnicotine), S-()-nicotine-5-
carboxaldehyde ((S)-nicotine-5-carboxaldehyde), (±)-6-
methylnicotine (6-methylnicotine), (S)-1-methylnicotinium iodide
((S)-1-methylnicotinium), (S)-1’-methylnicotinium iodide ((S)-1’-
methylnicotinium), (R, S)eN-ethyl nornicotine (homonicotine), N-
methyl anabasine were purchased from Toronto Research Chem-
icals (Toronto, ON, Canada).
Fig. 1. Crystal structure of Lst-AChBP bound with nicotine (PDB code: 1UW6) and the agonist-bound model of Asu-ACR-16.
(A) Ribbon diagram of the AChBP co-crystalized with nicotine, as viewed with membrane at the bottom. The principal subunit is highlighted by light pink and the complement
subunit is highlighted by light purple, for clarity. Nicotine (orange) is bound in the five ligand-binding sites in the extracellular domain of AChBP.
(B) Close view of the AChBP ligand-binding site. The principal subunit in light pink, the complementary subunit in light purple. Residues interacting with nicotine (orange) are
represented as sticks ((þ), pink; (), purple), and water molecule is shown as red dot, view with membrane at the bottom.
(C) Close view of the agonist-bound model of Asu-ACR-16 ligand-binding site. The principal subunit in light pink, the complementary subunit in light purple. The interacting
residues are represented as sticks ((þ), pink; (), purple), and water molecule is shown as red dot, view with membrane at the bottom. (D) Superposition of residues in agonist-
binding site, among agonist-bound form (blue), apo (no ligand) form (yellow), antagonist-bound form (green) of Asu-ACR-16 models are shown. (For interpretation of the references
to colour in this figure legend, the reader is referred to the web version of this article.)
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3. Results
3.1. Ligand-binding sites
Lst-AChBP (PDB code: 1UW6) (Celie et al., 2004) shows 23.33%
sequence identity and 64.29% sequence similarity to ECD-Asu-ACR-
16 (Fig. S4A) and is the only crystal structure of a protein homol-
ogous to Asu-ACR-16 co-crystalized with nicotine to date. The
ligand-binding site for agonist is at the interface between the
principal side and the complementary side in two adjacent sub-
units of nAChRs (Li et al., 2011; Rucktooa et al., 2012).
Nicotine adopts the same binding pose in all five ligand-binding
sites in Lst-AChBP pentamer (Fig. 1A). The pyrrolidine ring of
nicotine is oriented toward the basal side of the binding site on the
principal subunit, whereas the pyridine ring faces the apical side on
the complementary subunit. The protonated nitrogen (N2) in the
pyrrolidine ring of nicotine is involved in cation-p interactions,
mainly with W143 (on principal subunit) or maybe four aromatic
Fig. 2. Ligand-binding sites of Asu-ACR-16 and its homologous proteins.
(A) Surface representation in the open-up ligand-binding site of Lst-AChBP in complex with nicotine (PDB code: 1UW6). Oxygen-rich area (red), nitrogen-rich area (blue) and
carbon-rich area (gray) are displayed. Empty space was observed around the 5-pyridine ring of nicotine, which suggests that the ligand-binding site is in favor of the linear
functional group linking toward the 5-pyridine ring of nicotine. Little space is found around the pyrrolidine ring of nicotine.
(B) Surface representation in the open-up ligand-binding site of human a7 AChR chimera in complex with epibatidine (PDB code: 3SQ6), viewed by the same angle as (A). Oxygen-
rich area (red), nitrogen-rich area (blue), carbon-rich area (pink) and chloride (green) are displayed. The azabicyclic ring N1 of epibatidine was superimposed with the pyrrolidine
ring N2 of nicotine, while the pyridine ring N2 of epibatidine was superimposed with the pyridine ring N1 of nicotine.
(C) Surface representation in the open-up ligand-binding site of agonist-bound Asu-ACR-16 model, viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-rich area (blue)
and carbon-rich area (cyan) are displayed. Assuming the nicotine has the same binding pose as in (A) within the agonist-bound Asu-ACR-16, empty space around the 5-pyridine ring
and pyrrolidine ring of nicotine, which allows nicotinic derivatives with modification in these positions fit into to the binding site. The black arrow indicates the likely orientation of
the 5-pyridine ring moiety. (D) Surface representation in the open-up ligand-binding site of apo form Asu-ACR-16 model, viewed by the same angle as (A). Oxygen-rich area (red),
nitrogen-rich area (blue) and carbon-rich area (yellow) are displayed. Assuming the nicotine has the same binding pose as in (A) within apo form Asu-ACR-16, there would be empty
space around the 5-pyridine ring and pyrrolidine ring of nicotine, which would make the nicotinic derivatives with modification in these positions fit in the binding site. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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residues in the binding site (principal subunit: Y89, Y185, Y192;
complementary subunit: W53) (Fig. 1B). The N2 is also hydrogen-
bonded to the hydroxyl moiety of Y89 and W143 carbonyl back-
bone. Hydrophobic interactions from disulfide-bonded C187 and
C188 on loop C stabilize nicotine in the binding pocket. The pyri-
dine ring nitrogen of nicotine (N1) is hydrogen-bonded to a water
molecule, which is stabilized by the carbonyl backbone of L102 and
M114 amide backbone of the complementary subunit (Fig. 1B)
(Celie et al., 2004; Van Arnam and Dougherty, 2014).
Fig. 1C shows the ligand-binding site of the agonist-bound Asu-
ACR-16 dimer viewed from the same angle as Fig. 1B. The residues
involved in the binding site are highlighted in Fig. 1C and indicated
in Fig. S4A by arrows. The interacting residues in the binding site of
the agonist-bound Asu-ACR-16 model share similar orientations
with those in the binding site of Lst-AChBP. The hydrophobic,
hydrogen-bond and van der Waals contacts between nicotine and
AChBP were therefore predicted in Asu-ACR-16. Y117, W173, Y214,
Y221 from principal and W79 from complementary constitute the
aromatic cage, in which W173 contributes most to the cation-p
interaction with protonated tertiary amine or tetramethyl ammo-
nium salt of nicotine or its derivatives. The hydroxyl moiety of Y117
and W173 carbonyl backbone are hydrogen-bonded to the pro-
tonated tertiary amine or ammonium of the ligand. The carbonyl
backbone of N131 and I143 amide backbone from the comple-
mentary face have water-mediated hydrogen bond with the pyri-
dine ring N1 of the ligand.
Structural superimposition of the binding-site residues among
three different bound forms Asu-ACR-16 show details of confor-
mational changes of residues when the agonist is in the binding
pocket of the receptor. Of particular note is the inward movement
of vicinal cysteines toward pyrrolidine N2 of nicotine. The
antagonist-bound model has less steric hindrance in the open re-
ceptor binding site (Fig. 1D) (Huang et al., 2013).
The human a7 nAChR chimera (PDB code: 3SQ6) (Li et al., 2011)
shows 62.98% sequence identity and 80.29% nucleotide sequence
similarity with the extracellular domain of human a7 nAChR
(UniProtKB accession number: P36544). The residues constituting
the ligand-binding site are highly conserved between human a7
nAChR chimera and human a7 nAChR (Fig. S4B). The crystal
structure of human a7 nAChR chimera co-crystalized with epi-
batidine could be used to study the binding site of agonist-bound
human a7 nAChR. Comparison of the binding sites in Lst-AChBP
(Fig. 2A), human a7 nAChR chimera (Fig. 2B), agonist-bound Asu-
ACR-16 (Fig. 2C) and apo form of Asu-ACR-16 (Fig. 2D) reveals that
the 5-substituted pyridine derivatives of nicotine would be
favorable, withmore space for the binding site of the ECD-Asu-ACR-
16, but not for the human a7 nAChR. The black dotted arrows mark
the likely orientation of the functional group on the 5-pyridine
moiety of nicotine (Fig. 2C and D). Additionally, our docking re-
sults show that the 5-substituted pyridine ring approaches close to
the disulfide bonds of Asu-ACR-16 and that the pyrrolidine ring is
twisted downward in the binding site (Fig. S5).
3.2. Potency of nicotine derivatives
Initially we tested a range of nicotine analogues (compounds
labelled 3e5 & 7e17 in Table 2, Fig. 3) as agonists to further char-
acterize the pharmacological profile of Asu-ACR-16 receptors by
measuring agonist EC50, Imax and nH values. The EC50 for (S)-nicotine
was 6.21 ± 0.56 mM and the Imax was 82.39 ± 2.52%, N ¼ 5 (Table 2).
(S)-nicotine is a potent agonist of Asu-ACR-16, but can also activate
mammalian nAChRs and as an anthelmintic would also cause ef-
fects in the host (Chavez-Noriega et al., 1997). As a low-molecular-
weight andwater solublemolecule, (S)-nicotinewas selected as our
initial lead for further optimization (Bleicher et al., 2003). Using (S)-
nicotine as a pharmacophore and the predicted three-dimensional
structures of the Asu-ACR-16 ligand-binding site, we studied
structure-activity relationships by measuring the EC50, Imax and nH
values of the nicotine derivatives (Fig. 4, S6 and Table 2) on the Asu-
ACR-16 receptor. The agonist dose-response relationships for ACh
and (S)-nicotine (Fig. 5A), pyridine substituted nicotine derivatives
(Fig. 5B) and the pyrrolidine substituted nicotine derivatives
(Fig. 5C) are shown. The pyridine N1methylated substituent [(S)-1-
methylnicotium], the 5’-carbonylated pyrrolidine substituent [(S)-
cotinine], and the piperidine N2 methylated substituent [N-
methyl anabasine] did not act as agonists.
3.3. (S)-enantiomers are more potent
We compared the pharmacological profiles of (S)-anabasine and
its racemic mixture on Asu-ACR-16 (Fig. S7). The EC50 of (S)-ana-
basine was significantly lower than the EC50 of its racemic mixture
(P < 0.05, N ¼ 5). The Imax of (S)-anabasine was slightly higher than
that of its racemic mixture (P > 0.05, N ¼ 5). These results are
consistent with other published results that illustrate the higher
intrinsic activities of (S)-enantiomer nicotine alkaloids rather than
their (R)-enantiomer (Cosford et al., 2000). Therefore, subsequent
synthesis of compounds was directed towards preparation of (S)-
enantiomers.
Table 2
Pharmacological profiles of ACh, nicotine and fifteen nicotine derivatives. Results (mean ± S.E.M.) were expressed as the EC50 (mM), Hill slope (nH) andmaximum response (Imax,
%), number of repeats of each agonist experiment (Nagonist). One oocyte was used in each replicate of experiment.
No: Compound name EC50 (mM) nH Imax (%) Nagonist
1: (S)-5-ethynyl-anabasine 0.14 ± 0.01 1.81 ± 0.24 79.33 ± 3.75 5
2: (S)-5- bromoanabasine 0.32 ± 0.03 4.19 ± 1.58 80.69 ± 2.87 5
3: (S)eSIB 1508Y 0.37 ± 0.10 0.94 ± 0.04 100.1 ± 4.36 5
4: 5-methylnicotine 0.99 ± 0.17 2.09 ± 0.14 76.05 ± 1.22 5
5: (S)-anabasine 1.26 ± 0.19 2.26 ± 0.20 84.82 ± 4.20 5
6: (S)-5-bromonicotine 2.04 ± 0.12 2.46 ± 0.21 69.66 ± 3.28 5
7: 6-methylnicotine 6.13 ± 0.53 3.25 ± 0.24 69.74 ± 1.56 5
8: (S)-nicotine 6.21 ± 0.56 3.39 ± 0.36 82.39 ± 2.52 5
9: ACh 6.36 ± 0.49 2.93 ± 0.13 97.42 ± 0.93 5
10: (S)-1’- methylnicotinium 10.25 ± 0.62 3.52 ± 0.26 93.38 ± 5.25 5
11: (S)-nicotine-5-carboxaldehyde 11.51 ± 0.63 8.61 ± 4.04 62.20 ± 6.80 5
12: 6-AN 12.18 ± 0.29 10.10 ± 0.15 6.29 ± 0.62 5
13: homonicotine 16.62 ± 1.44 6.78 ± 2.50 22.01 ± 1.39 5
14: nornicotine 25.73 ± 4.71 3.25 ± 0.49 62.64 ± 3.42 5
15: N-methyl anabasine <100
16: (S)-1- methylnicotinium <100
17: (S)-cotinine <100
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3.4. (S) -5-ethynyl-anabasine, (S)-5-bromoanabasine and (S)-5-
bromonicotine
Examination of the structures and EC50 potencies of (S)eSIB
1508Y and (S)-anabasine suggested that a novel compound, (S)-5-
ethynyl-anabasine, would yield a more potent agonist. Conse-
quently, it was synthesized, as described in themethods, alongwith
(S)-5-bromonicotine and (S)-5-bromoanabsine that were produced
during its synthesis. The three novel synthesized compounds were
then tested on the Asu-ACR-16 receptor. The concentration
response plots for these compounds revealed that two of the novel
compounds, (S)-5-ethynyl-anabasine and (S)-5-bromoanabsine
were the most potent agonists tested to date (Fig. 5C & Table 2).
Fig. 3. Chemical structures of (S)-nicotine and fifteen derivatives studied. 5-substituted pyridine ring derivatives: (S)eSIB 1508Y, (S)-5-bromonicotine, (S)-nicotine-5-
carboxaldehyde and 5-methylnicotine; other pyridine ring substituted derivatives: (S)-1-methylnicotinium, 6-methylnicotine and 5-(1-methyl-pyrrolidin-2-yl)-pyridin-2-
ylamine (6-AN); pyrrolidine ring substituted derivatives: (S)-1’-methylnicotinium, homonicotine, nornicotine and (S)-cotinine; piperidine ring derivatives: (S)-5-ethynyl-anaba-
sine, (S)-5-bromoanabasine, (S)-anabasine and N-methyl anabasine are shown.
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3.5. Agonist rank order potency
Fig. 5 shows the dose-response plots for the most potent ago-
nists. The rank order of potency the agonists based on the EC50
values, Table 2, was: (S)-5-ethynyl-anabasine > (S)-5-
bromoanabasine z (S)eSIB 1508Y > 5-methylnicotine z (S)-
anabasine > (S)-5-bromonicotine > 6-methylnicotine z (S)-
nicotine z ACh > (S)-1’-methylnicotinium z (S)-nicotine-5-
carboxaldehyde z 6-AN > homonicotine z nornicotine. Two
piperidine ring derivatives: (S)-5-bromoanabasine and (S)-anaba-
sine, two 5-substituted pyridine derivatives: (S)eSIB 1508Y and 5-
methylnicotine were more potent than ACh and (S)-nicotine
(P < 0.05, N ¼ 5). The EC50 of the novel lead compound, (S)-5-
ethynyl-anabasine, is 44 times lower (more potent) than its initial
pharmacophore, (S)-nicotine, and is themost potent agonist of Asu-
ACR-16.
3.6. Correlation between affinity and potency among nicotine
derivatives
The binding affinities of the selected nicotine derivatives were
calculated for ligands docking into the agonist-binding site in the
agonist-bound form, the apo (no ligand) form and the antagonist-
bound form ECD-Asu-ACR-16 models. We examined the relation-
ship between the binding affinities and the observed values of the
expressed receptors for the EC50 (mM) of the nicotine derivatives.
There was a positive correlation (þ0.66) between the binding af-
finity and the EC50 of the apo form model (P < 0.05) (Fig. 6); the
correlation with the agonist bound Asu-ACR-16 (0.36) and antag-
onist bound Asu-ACR-16 (0.46) were smaller and did not reach
Fig. 4. Sample concentration-current recording traces for the most potent nicotine derivatives on the Asu-ACR-16 receptor. (S)-5-ethynyl-anabasine (A), (S)-5-bromoanabasine (B),
(S)eSIB 1508Y (C), 5-methylnicotine (D) are depicted. For each nicotine derivative, 5 oocyte were tested as replicates. Resting membrane potential clamped at 60 mV. Downward
responses to exposure of the agonists show opening of the ion-channel. Peak responses were recorded, normalized and fitted into the Hill equations.
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statistical significance (P > 0.05). The highest correlation with the
apo form suggests that this model is more likely to predict the
potency of unknown agonists than the other models of the
receptor.
4. Discussion
4.1. Structure-activity relationships of nicotine derivatives on Asu-
ACR-16
4.1.1. Pyridine ring substituted derivatives
We studied the effects of functional groups added to the
different positions of pyridine moiety of nicotine: the methyl group
substituted at the 5- or 6- or N-pyridine moiety of nicotine, and an
amino group substituted at the 6-pyridine moiety of nicotine. 5-
Methylnicotine was the most potent agonist, while 6-
methylnicotine was slightly less potent. 6-AN showed little
agonist activity. The electron-donating group of the methyl or the
amino at the 5- or 6-pyridine increased the electronegativity and
alkalinity of the pyridine N1, and so stabilized the water-mediated
hydrogen bondwith the carbonyl backbone of N131 and I143 amide
backbone from the complementary subunit of the receptor. The
lone pair electrons on the pyridine N1 of (S)-1-methylnicotinium
were replaced by the methyl group. As a result N1 cannot
hydrogen-bond with the carbonyl backbone of N131 and I143
amide backbone from the receptor so that this reduces the intrinsic
activity of N-pyridine substituted derivatives.
Fig. 5. Dose-response curves of nicotine derivatives for Asu-ACR-16. For experiment of each nicotine derivative, one oocyte was used as a group. Five replicates were performed for
each group. Current responses are normalized to the first 100 mM control application (Methods).
(A) ACh and (S)-nicotine as two controls.
(B) Pyridine ring substituted derivatives. Responses of 30 mM 5-methylnicotine and 100 mM 6-methylnicotine are shown but were not included for fitting the Hill equation to
estimate EC50, nH and Imax correspondingly due to their inhibitory effects at high concentrations.
(C) Pyrrolidine ring substituted derivatives. Response of 300 mM homonicotine is shown but was not included for fitting the Hill equation to estimate EC50, nH and Imax due to its
inhibitory effect at high concentration.
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4.1.2. 5-substituted pyridine derivatives
Given that the electron-donating groups at the 5-pyridine of
nicotine were found to have the highest potency as agonists, the
electron-withdrawing groups of acetylene, bromine or aldehyde
derivatives at the 5-pyridine position of nicotine were selected for
testing. (S)eSIB 1508 was the most potent agonist, while (S)-5-
bromonicotine and (S)-nicotine-5-carboxaldehyde were less
potent. The extra cavity within the binding site of Asu-ACR-16
agonist-bound and apo model could accommodate the linear
acetylene substituent and globular bromine atom at the 5-pyridine
ring of nicotine, allowing the ligands to extend into unoccupied
space (Fig 2CD, top left quadrants of the binding pocket). The bent
structure of aldehyde appears to be less favored in the binding
pocket. Our docking studies showanother possible reason for the 5-
substituted pyridine derivatives to stabilize Asu-ACR-16. Fig. S5B&C
show that the 5-substituted pyridine ring approaches towards the
close-in conformation of the vicinal cysteines, which is a typical
feature of the activated state of AChRs.
4.1.3. Pyrrolidine ring substituted derivatives
To study the effects of functional groups added to the different
positions of pyrrolidine moiety of nicotine, a methyl or ethyl group
was added at the N-pyrrolidine moiety of nicotine, and a ketone
group was added at the 5’-pyrrolidine moiety of nicotine. The
additional methyl group linked to the pyrrolidine N2 of (S)-1’-
methylnicotinium produces a quaternary ammonium, which in-
creases the cation-p interaction with the five aromatic residues
from the ACR-16 receptor, but increases the steric hindrance around
the pyrrolidine N2 making this compound stereochemically unfa-
vorable. The increased steric hindrance due to the ethyl group at
pyrrolidine N2 of homonicotine may be the reason for its reduced
agonist potency. The secondary amine of nornicotine reduces the
alkalinity and the probability of making a cation-p interaction with
the receptor. The conjugative effect of the lone pair of electrons on
the pyrrolidine N2 of (S)-cotinine to the p bond of carbonyl group,
causes the pyrrolidine N2 to be hardly protonated, which signifi-
cantly limits the cation-p interaction with the aromatic cage from
the receptor and its action as an agonist.
4.1.4. Piperidine ring derivatives
The N-methyl pyrrolidine moiety was replaced by an N-methyl
piperidine ring in nicotine structure to study the effect of increasing
the membrane ring on the stimulatory activity of Asu-ACR-16. We
found that N-methyl anabasine was inactive, but when the N-
methyl group of the piperidine moiety was removed, the com-
pound was a potent agonist. The piperidine ring of (S)-anabasine
may have sterically and electrostatically stabilized the aromatic
cage on the receptor better than the N-methylated pyrrolidine ring
of nicotine. The novel lead compound, (S)-5-ethynyl-anabasine
contains two moieties favorable to the Asu-ACR-16 ligand-binding
site: an electron-withdrawing group at the 5-pyridine of nicotine
moiety ((S)eSIB 1508Y) and; the piperidine moiety ((S)-anabasine).
(S)-5-ethynyl-anabasine shows high potency (EC50 0.14 ± 0.01 mM,
N ¼ 5) as an agonist.
4.2. Docking study as a probe for searching potent Asu-ACR-16
agonist
The potency (EC50) of the selected nicotinic alkaloids was
correlated more with the binding affinity in the apo model of Asu-
ACR-16 than with the agonist- or antagonist-bound model of Asu-
ACR-16. This appears to be due to the different conformation
changes of vicinal cysteines or the opened-up orientation ofW79 in
the agonist-bound and antagonist-bound models of Asu-ACR-16,
which reduces the cation-p interaction between W79 and nicotine
N2 (Blum et al., 2010; Van Arnam and Dougherty, 2014). The sta-
tistical correlation between the predicted ligand binding affinities
in the apo model of Asu-ACR-16 and their corresponding potencies
(EC50), suggests that the apo model would be more helpful when
searching for potent agonists by docking.
5. Conclusion
We used structural models of the ECD-Asu-ACR-16 agonist-
binding site and expressed receptor to study the structure-
activity relationships of several nicotine alkaloids on Asu-ACR-16
receptor. We synthesized a novel compound, (S)-5-ethynyl-ana-
basine, which was 44 times more potent than (S)-nicotine as an
Asu-ACR-16 agonist. Our structure-based drug discovery of ACR-16
agonists also suggests several other nicotine alkaloids as leads for
further development.
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Fig. 6. Correlations between binding affinities (kcal/mol) of each derivative in the apo
form Asu-ACR-16 and EC50 (mM) (A), binding affinities (kcal/mol) for the selected
nicotine derivatives. The correlation coefficients (r) was used for evaluating the linear
regression between affinities and pharmacological parameters (r ¼ 0.66, P < 0.05).
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